Highest-materiality recent filing
Pulmatrix Q2 net loss $1.0M; cash $2.2M; merger with Eos on track for Q3 close
Q2 net loss $1.036M ($0.29/share) vs $1.549M loss year ago; R&D expenses <$0.1M.
Pulmatrix Q1 net loss $1.2M, cash $3.3M; merger with Eos SENOLYTIX set for Q3 2026
Net loss $1.172M ($0.32/share) vs $1.808M ($0.50/share) in Q1 2025; no revenue reported.
Pulmatrix closes $1M Series B preferred placement as part of planned merger with Eos
Gross proceeds of approximately $1 million from Series B Preferred Stock issued to Eos affiliate.
Pulmatrix to merge with Eos SENOLYTIX; Eos stockholders to own ~94% of combined company
Pre-Merger Eos stockholders to own ~94% of combined company; Pulmatrix stockholders ~6% on fully-diluted basis.
Pulmatrix merger with Cullgen terminated; seeks alternative merger opportunities
Cullgen terminated the Merger Agreement on Feb 28, 2026 citing failure to obtain China Securities Regulatory Commission approval.
Pulmatrix: $0 revenue in 2025, net loss $5.2M, plans to license iSPERSE
Revenue $0 in 2025 vs $7.8M in 2024; net loss $5.2M ($1.41/share) vs $9.6M.
Pulmatrix and Cullgen waive no-solicitation clause, explore alternatives due to CSRC delay
Parties mutually waived the 'No Solicitation' clause (Section 5.4) of the Nov 2024 Merger Agreement.
Pulmatrix Q3 net loss $877K; pursues asset divestment for Cullgen merger
Net loss $877K ($0.24 per share); revenues $0 vs $0.4M YoY; cash $4.8M sufficient into Q4 2026.
Revenue fell to $0 from $1.6M in Q2 2024 due to PUR1900 wind-down; net loss $1.549M ($0.42 per share).
Pulmatrix stockholders approve merger proposals; CSRC clearance still outstanding
All seven proposals approved by stockholders at June 16 special meeting, including issuance of shares for Cullgen merger.
Pulmatrix reports Q1 loss; plans asset divestment, Cullgen merger close targeted for June
Q1 2025 revenue $0 vs $5.9M YoY; net loss $1.8M (-$0.50 EPS) vs net income $0.825M in Q1 2024.
Pulmatrix and Cullgen amend merger agreement to one-step merger; Second Merger Sub removed
Amendment No. 1 dated April 7, 2025 changes transaction from two-step to one-step merger, eliminating Second Merger Sub.
Pulmatrix auditor change: Marcum resigns, CBIZ engaged effective April 4, 2025
Marcum LLP resigned as independent auditor on April 4, 2025; no adverse opinions or disagreements in prior reports.
Pulmatrix reports 2024 net loss of $9.6M; proposes merger with Cullgen and asset divestment
Net loss for 2024 of $9.6M ($2.62 per share) vs $14.1M ($3.87 per share) in 2023.
Pulmatrix amends bylaws to revise voting standards language
Board approved Amendment No. 2 on Feb 11, 2025, effective immediately.
Pulmatrix stockholders elect two Class I directors, ratify auditor at 2024 annual meeting
Elected Todd Bazemore and Christopher Cabell as Class I directors with votes for 285,646 and 334,230, respectively.
Pulmatrix to merge with Cullgen in reverse merger; Cullgen holders to own 96.4%
Pulmatrix to merge with Cullgen; exchange ratio implies Cullgen valuation of $280M, Pulmatrix $10.5M.
Pulmatrix Q3 2024 revenue down 79% YoY to $0.4M; cash runway into Q4 2026
Net loss $2.6M ($0.71 per share) vs $3.8M ($1.03) in Q3 2023.
Pulmatrix sets 2024 annual meeting for Dec 18; Oct 31 record date
2024 Annual Meeting scheduled for Wednesday, December 18, 2024.
Pulmatrix Q2 2024 net loss widens to $5.8M; cash runway extended to Q4 2026
Net loss widened to $5.8M ($1.59/sh) from $3.8M ($1.04) a year ago; revenue fell to $1.6M from $1.8M.
CEO Teofilo Raad departs Pulmatrix; Peter Ludlum appointed Interim CEO
Teofilo Raad separated as CEO and Board member effective July 19, 2024; severance includes $567,294 salary, $156,310 prorated bonus, $283,647 separation bonus.
Pulmatrix cross-licenses iSPERSE with MannKind; transfers Bedford R&D facility to extend cash runway
Pulmatrix grants MannKind exclusive iSPERSE licenses for clofazimine, NTM lung disease, insulin; non-exclusive for endocrine, ILD.
All PUR3100 doses showed mean Cmax above 1000 pg/mL efficacy threshold; Tmax 5 min vs 5.5 min for IV DHE.
Pulmatrix Q1 rev $5.9M, net income $0.8M; PUR1900 study wind down, cash runway into Q1 2026
Revenue $5.9M (up $4.4M YoY) due to Cipla contract modification catch-up.
Pulmatrix reports FY2023 net loss narrowed; cash runway extended to Q1 2026 on Cipla amendment
Cash and equivalents $19.2M at Dec 31, 2023; projected runway into Q1 2026.
Pulmatrix terminates CMO Dr. Margaret Wasilewski; transitions to outsourced part-time CMO model
Terminated CMO Dr. Margaret Wasilewski on March 7, 2024; position eliminated for transition to outsourced part-time CMO model.
Pulmatrix furnishes corporate presentation for March 2024; content not provided in filing
Filed under Item 7.01 as a Regulation FD disclosure of a slide presentation dated March 2024.
Pulmatrix halts PUR1900 Ph2b study; Cipla assumes ex-US development for 2% royalty
Enrollment stopped at 8 subjects; study wind-down expected by July 2024; Pulmatrix's cash burn significantly reduced.
Pulmatrix Q3 2023 net loss $3.8M; cash $21.3M, runway into Q1 2025
Revenue $1.8M (-$0.1M YoY); net loss $3.8M ($1.03/share) vs $5.1M loss in prior year.
Pulmatrix Q2 2023: cash $25.8M, net loss $3.8M; PUR1900 Phase 2b enrollment ongoing, topline Q3 2024
Cash and cash equivalents $25.8M as of June 30, 2023; projected runway into Q1 2025.
Pulmatrix shareholders elect directors, ratify auditor; say-on-pay passes narrowly
Elected Michael J. Higgins (758,720 for, 533,500 withheld) and Anand Varadan (1,014,129 for, 278,091 withheld) as Class III directors until 2026.
Pulmatrix submits IND for PUR3100 Phase 2 trial in acute migraine
IND submitted to FDA for PUR3100, an inhaled dry powder DHE formulation for acute migraine.
Pulmatrix reports Q1 net loss $4.45M; cash runway extended to Q4 2024
Net loss of $4.45M ($1.22 per share) vs $4.97M loss in Q1 2022.
Pulmatrix reports FY2022 revenue $6.1M, net loss $18.8M; cash $35.6M into Q2 2024
Revenue $6.1M (+$0.9M YoY); net loss $18.8M vs $20.2M; EPS -$5.46 vs -$8.63.
Pulmatrix doses first patient in Phase 2b trial of PUR1900 for ABPA with asthma
First patient dosed in randomized, double-blind, placebo-controlled Phase 2b study of inhaled itraconazole (PUR1900) for ABPA in asthma.
Pulmatrix 8-K attaches slide deck for KOL event; no material facts disclosed in filing
Filing provides no specific financial, clinical, or operational data; slide content not included in excerpt.
Pulmatrix to host KOL webinar on PUR3100 for acute migraine on Feb 3, 2023
Webinar on Feb 3, 2023 at 10:00 AM ET, featuring Prof. Stewart Tepper (Dartmouth).
Pulmatrix furnishes January 2023 investor presentation; no material details in filing
The filing includes a slide presentation for use at investor conferences, but the presentation content is not provided in the extracted text.
PUR3100 was safe and well-tolerated; no emesis in any dose group; lower nausea incidence vs IV DHE.
Pulmatrix reports Q3 2022 revenue $1.9M, net loss $5.05M; PUR1900 Phase 2 on track for Q1 2023
Revenues $1.9M, up from $1.1M YoY; net loss $5.05M ($1.45 per share) vs $8.18M loss in prior year.
All 26 healthy subjects completed dosing in double-blind, double-dummy Phase 1 trial of PUR3100 (inhaled DHE) vs IV DHE.
Pulmatrix Q2 revenue falls 41% to $1.3M; net loss widens to $4.6M; cash $42.9M
Q2 2022 revenue $1.3M vs $2.2M in Q2 2021; decrease driven by no PUR1800 revenue offset by Cipla agreement for Pulmazole.
Pulmatrix doses first subjects in Phase 1 trial of inhaled DHE (PUR3100) for acute migraine
First five subjects dosed in Phase 1 trial of PUR3100, an inhaled formulation of dihydroergotamine (DHE) using iSPERSE technology.
Pulmatrix reports annual meeting vote results; directors elected, auditor ratified
1,490,945 shares (44.02% of outstanding) present, constituting a quorum.
Pulmatrix Q1 net loss widens to $5.0M; cash $47.5M extends runway to Q2 2024
Net loss of $5.0M ($1.51 per share) vs $4.1M loss in Q1 2021; revenue fell to $1.2M from $1.4M.
Pulmatrix reduces stockholder quorum requirement from majority to one-third
Board approved bylaw amendment lowering quorum to one-third of voting power.
Pulmatrix appoints Peter Ludlum as Interim CFO effective April 18, 2022
Peter Ludlum appointed Interim CFO, Principal Accounting Officer, and Principal Financial Officer effective April 18, 2022.
Pulmatrix reports 2021 revenue $5.2M, net loss $20.2M; cash $53.8M; pipeline milestones set
Revenue $5.2M in 2021 vs $12.6M in 2020; net loss $20.2M vs $19.3M; EPS ($8.63).
Pulmatrix reports positive Phase 1b top-line data for PUR1800 in stable COPD
PUR1800 well-tolerated with no safety signals in 18-subject Phase 1b study.
Pulmatrix regains compliance with Nasdaq minimum bid price requirement
Received Nasdaq notice on March 15, 2022 that minimum bid price compliance is regained.
the Board approved the appointment of Peter Ludlum as the Interim Chief Executive Officer (the “Interim CEO”), effective as of July 20, 2024
Effective as of the Separation Date, Mr. Raad’s employment with the Company shall cease and Mr. Raad shall relinquish all positions, offices, and authority with the Company and any affiliates, including as a member of the Board
On March 7, 2024, the Board of Directors of Pulmatrix, Inc. (the “Company”) approved the termination of the Company’s Chief Medical Officer (“CMO”), Dr. Margaret Wasilewski’s, employment with the Company.
On April 14, 2022, the Board of Directors of Pulmatrix, Inc. (the “Company”) appointed Peter Ludlum as Interim Chief Financial Officer of the Company, effective as of April 18, 2022, to serve until a successor is chosen and qualified, or until his earlier resignation or removal.
On July 23, 2021, Anand Varadan was appointed to the board of directors of the Company, effective as of July 26, 2021, to serve as a Class III director
On July 23, 2021, Mark Iwicki resigned from the board of directors of Pulmatrix, Inc. (the “Company”).
Max materiality 1.00 · Median 0.60 · Most common event earnings